Vaccines against extraintestinal pathogenic Escherichia coli (ExPEC): progress and challenges

Ling Qiu Dylan Chirman Justin R. Clark Yikun Xing Haroldo Hernandez Santos Ellen E. Vaughan Anthony W. Maresso a Department of Molecular Virology and Microbiology,Baylor College of Medicine,Houston,TX,USAb Tailored Antibacterials and Innovative Laboratories for Phage (Φ) Research (TAILΦR),Baylor College of Medicine,Houston,TX,USA

DOI: https://doi.org/10.1080/19490976.2024.2359691

IF: 12.2

2024-06-03

Gut Microbes

Abstract:The emergence of antimicrobial resistance (AMR) is a principal global health crisis projected to cause 10 million deaths annually worldwide by 2050. While the Gram-negative bacteria Escherichia coli is commonly found as a commensal microbe in the human gut, some strains are dangerously pathogenic, contributing to the highest AMR-associated mortality. Strains of E. coli that can translocate from the gastrointestinal tract to distal sites, called extraintestinal E. coli (ExPEC), are particularly problematic and predominantly afflict women, the elderly, and immunocompromised populations. Despite nearly 40 years of clinical trials, there is still no vaccine against ExPEC. One reason for this is the remarkable diversity in the ExPEC pangenome across pathotypes, clades, and strains, with hundreds of genes associated with pathogenesis including toxins, adhesins, and nutrient acquisition systems. Further, ExPEC is intimately associated with human mucosal surfaces and has evolved creative strategies to avoid the immune system. This review summarizes previous and ongoing preclinical and clinical ExPEC vaccine research efforts to help identify key gaps in knowledge and remaining challenges.

gastroenterology & hepatology,microbiology

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is the challenges in developing effective vaccines against extra - intestinal pathogenic Escherichia coli (ExPEC). Despite nearly 40 years of clinical trials, there are still no vaccines against ExPEC at present. ExPEC can transfer from the gastrointestinal tract to other parts of the body, causing a variety of diseases, especially urinary tract infections (UTI), which are very common and difficult to be completely cured. In addition, antibiotic - resistant ExPEC strains are constantly emerging globally, which increases the complexity of treating these infections. Therefore, the development of effective ExPEC vaccines is of great significance for preventing these diseases.

By reviewing previous ExPEC vaccine research, the paper aims to summarize the existing research results and identify key knowledge gaps and remaining challenges. This includes evaluating the performance of different types of vaccines (such as traditional vaccines, polysaccharide - conjugate vaccines and protein subunit vaccines) in pre - clinical and clinical studies, and discussing how to overcome the challenges brought by ExPEC antigen diversity.